Abstract 10947: Sacubitril/Valsartan versus Spironolactone in Heart Failure with Preserved Ejection Fraction; A Cost per Outcome Analysis

Gal Tsaban,Hilmi Alnsasra,Ala Abu Dogosh,Itai Weissberg,Yael Ben-Baruch Golan,Orit Barrett,Roi Westreich,Enis Aboalhasan,Joseph Azuri,Ariel Hammerman,Ronen Arbel

Abstract 10947: Sacubitril/Valsartan versus Spironolactone in Heart Failure with Preserved Ejection Fraction; A Cost per Outcome Analysis

2021

Gal Tsaban
Hilmi Alnsasra
Ala Abu Dogosh
Itai Weissberg
Yael Ben-Baruch Golan
Orit Barrett
Roi Westreich
Enis Aboalhasan
Joseph Azuri
Ariel Hammerman
Ronen Arbel

Introduction: Heart failure with preserved ejection fraction (HFpEF) is associated with frequent hospitalizations and an increased risk of death. There are no therapies with certain benefits for th...

Keywords:

outcome analysis
Cardiology
Heart failure with preserved ejection fraction
increased risk
Heart failure
Internal medicine
Spironolactone
Medicine
Sacubitril, Valsartan

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations